• PolyNovo confirms confidential discussion with CEO regarding his departure
• Non-executive director to step in as Acting CEO pending permanent replacement
• PolyNovo is a disruptive ASX 200 medical technology company

PolyNovo Limited (ASX: PNV) has released an ASX announcement in response to an article in the 'Margin Call' column of The Australian newspaper. The company confirms that there was a confidential discussion with the Chief Executive Officer, Mr Swami Raote, last week, requesting his agreement to cease employment with PNV effective June 2025 at the end of his contractual notice period and to step down as CEO at an earlier date. The discussion proposed terms for his separation if agreement was reached and revealed that non-executive director, Dr Robyn Elliott, would be stepping into the role as Acting Chief Executive Officer pending the appointment of a permanent replacement. PolyNovo is a disruptive ASX 200 medical technology company based in Melbourne, Australia, which simplifies the management of acute complex wounds and redefines healing with differentiated patient outcomes across multiple wound etiologies. The company has treated over 50,000 patients across 41 countries and is investing for growth via new products, indications, and markets.